Chengchen Hu1, Kimberly Wang1, Ceylan Damon1, Yi Fu1, Tengjiao Ma1, Lisa Kratz2, Bachchu Lal1,2, Mingyao Ying1,2, Shuli Xia1,2, Daniel P Cahill3, Christopher M Jackson4, Michael Lim4, John Laterra1,2,5,6, Yunqing Li1,2. 1. Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland, USA. 2. Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 3. Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. 4. Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 5. Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 6. Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
BACKGROUND: ATRX inactivation occurs with IDH1R132H and p53 mutations in over 80% of Grades II/III astrocytomas. It is believed that ATRX loss contributes to oncogenesis by dysregulating epigenetic and telomere mechanisms but effects on anti-glioma immunity have not been explored. This paper examines how ATRX loss contributes to the malignant and immunosuppressive phenotypes of IDH1R132H/p53mut glioma cells and xenografts. METHODS: Isogenic astrocytoma cells (+/-IDH1R132H/+/-ATRXloss) were established in p53mut astrocytoma cell lines using lentivirus encoding doxycycline-inducible IDH1R132H, ATRX shRNA, or Lenti-CRISPR/Cas9 ATRX. Effects of IDH1R132H+/-ATRXloss on cell migration, growth, DNA repair, and tumorigenicity were evaluated by clonal growth, transwell and scratch assays, MTT, immunofluorence and immunoblotting assays, and xenograft growth. Effects on the expression and function of modulators of the immune microenvironment were quantified by qRT-PCR, immunoblot, T-cell function, macrophage polarization, and flow cytometry assays. Pharmacologic inhibitors were used to examine epigenetic drivers of the immunosuppressive transcriptome of IDH1R132H/p53mut/ATRXloss cells. RESULTS: Adding ATRX loss to the IDH1R132H/p53mut background promoted astrocytoma cell aggressiveness, induced expression of BET proteins BRD3/4 and an immune-suppressive transcriptome consisting of up-regulated immune checkpoints (e.g., PD-L1, PD-L2) and altered cytokine/chemokine profiles (e.g., IL33, CXCL8, CSF2, IL6, CXCL9). ATRX loss enhanced the capacity of IDH1R132H/p53mut cells to induce T-cell apoptosis, tumorigenic/anti-inflammatory macrophage polarization and Treg infiltration. The transcriptional and biological immune-suppressive responses to ATRX loss were enhanced by temozolomide and radiation and abrogated by pharmacologic BET inhibition. CONCLUSIONS: ATRX loss activates a BRD-dependent immune-suppressive transcriptome and immune escape mechanism in IDH1R132H/p53mut astrocytoma cells.
BACKGROUND: ATRX inactivation occurs with IDH1R132H and p53 mutations in over 80% of Grades II/III astrocytomas. It is believed that ATRX loss contributes to oncogenesis by dysregulating epigenetic and telomere mechanisms but effects on anti-glioma immunity have not been explored. This paper examines how ATRX loss contributes to the malignant and immunosuppressive phenotypes of IDH1R132H/p53mut glioma cells and xenografts. METHODS: Isogenic astrocytoma cells (+/-IDH1R132H/+/-ATRXloss) were established in p53mut astrocytoma cell lines using lentivirus encoding doxycycline-inducible IDH1R132H, ATRX shRNA, or Lenti-CRISPR/Cas9 ATRX. Effects of IDH1R132H+/-ATRXloss on cell migration, growth, DNA repair, and tumorigenicity were evaluated by clonal growth, transwell and scratch assays, MTT, immunofluorence and immunoblotting assays, and xenograft growth. Effects on the expression and function of modulators of the immune microenvironment were quantified by qRT-PCR, immunoblot, T-cell function, macrophage polarization, and flow cytometry assays. Pharmacologic inhibitors were used to examine epigenetic drivers of the immunosuppressive transcriptome of IDH1R132H/p53mut/ATRXloss cells. RESULTS: Adding ATRX loss to the IDH1R132H/p53mut background promoted astrocytoma cell aggressiveness, induced expression of BET proteins BRD3/4 and an immune-suppressive transcriptome consisting of up-regulated immune checkpoints (e.g., PD-L1, PD-L2) and altered cytokine/chemokine profiles (e.g., IL33, CXCL8, CSF2, IL6, CXCL9). ATRX loss enhanced the capacity of IDH1R132H/p53mut cells to induce T-cell apoptosis, tumorigenic/anti-inflammatory macrophage polarization and Treg infiltration. The transcriptional and biological immune-suppressive responses to ATRX loss were enhanced by temozolomide and radiation and abrogated by pharmacologic BET inhibition. CONCLUSIONS: ATRX loss activates a BRD-dependent immune-suppressive transcriptome and immune escape mechanism in IDH1R132H/p53mut astrocytoma cells.
Authors: Brett E Johnson; Tali Mazor; Chibo Hong; Michael Barnes; Koki Aihara; Cory Y McLean; Shaun D Fouse; Shogo Yamamoto; Hiroki Ueda; Kenji Tatsuno; Saurabh Asthana; Llewellyn E Jalbert; Sarah J Nelson; Andrew W Bollen; W Clay Gustafson; Elise Charron; William A Weiss; Ivan V Smirnov; Jun S Song; Adam B Olshen; Soonmee Cha; Yongjun Zhao; Richard A Moore; Andrew J Mungall; Steven J M Jones; Martin Hirst; Marco A Marra; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchel S Berger; Susan M Chang; Barry S Taylor; Joseph F Costello Journal: Science Date: 2013-12-12 Impact factor: 47.728
Authors: Eri Ochiai; Qila Sa; Morgan Brogli; Tomoya Kudo; Xisheng Wang; Jitender P Dubey; Yasuhiro Suzuki Journal: Am J Pathol Date: 2014-11-26 Impact factor: 4.307
Authors: Lukas Bunse; Stefan Pusch; Theresa Bunse; Felix Sahm; Khwab Sanghvi; Mirco Friedrich; Dalia Alansary; Jana K Sonner; Edward Green; Katrin Deumelandt; Michael Kilian; Cyril Neftel; Stefanie Uhlig; Tobias Kessler; Anna von Landenberg; Anna S Berghoff; Kelly Marsh; Mya Steadman; Dongwei Zhu; Brandon Nicolay; Benedikt Wiestler; Michael O Breckwoldt; Ruslan Al-Ali; Simone Karcher-Bausch; Matthias Bozza; Iris Oezen; Magdalena Kramer; Jochen Meyer; Antje Habel; Jessica Eisel; Gernot Poschet; Michael Weller; Matthias Preusser; Minou Nadji-Ohl; Niklas Thon; Michael C Burger; Patrick N Harter; Miriam Ratliff; Richard Harbottle; Axel Benner; Daniel Schrimpf; Jürgen Okun; Christel Herold-Mende; Sevin Turcan; Stefan Kaulfuss; Holger Hess-Stumpp; Karen Bieback; Daniel P Cahill; Karl H Plate; Daniel Hänggi; Marion Dorsch; Mario L Suvà; Barbara A Niemeyer; Andreas von Deimling; Wolfgang Wick; Michael Platten Journal: Nat Med Date: 2018-07-09 Impact factor: 53.440
Authors: Aram S Modrek; Danielle Golub; Themasap Khan; Devin Bready; Jod Prado; Christopher Bowman; Jingjing Deng; Guoan Zhang; Pedro P Rocha; Ramya Raviram; Charalampos Lazaris; James M Stafford; Gary LeRoy; Michael Kader; Joravar Dhaliwal; N Sumru Bayin; Joshua D Frenster; Jonathan Serrano; Luis Chiriboga; Rabaa Baitalmal; Gouri Nanjangud; Andrew S Chi; John G Golfinos; Jing Wang; Matthias A Karajannis; Richard A Bonneau; Danny Reinberg; Aristotelis Tsirigos; David Zagzag; Matija Snuderl; Jane A Skok; Thomas A Neubert; Dimitris G Placantonakis Journal: Cell Rep Date: 2017-10-31 Impact factor: 9.423
Authors: Elizabeth B Claus; Kyle M Walsh; John K Wiencke; Annette M Molinaro; Joseph L Wiemels; Joellen M Schildkraut; Melissa L Bondy; Mitchel Berger; Robert Jenkins; Margaret Wrensch Journal: Neurosurg Focus Date: 2015-01 Impact factor: 4.047
Authors: Steven M Chan; Daniel Thomas; M Ryan Corces-Zimmerman; Seethu Xavy; Suchita Rastogi; Wan-Jen Hong; Feifei Zhao; Bruno C Medeiros; David A Tyvoll; Ravindra Majeti Journal: Nat Med Date: 2015-01-19 Impact factor: 87.241
Authors: Nduka M Amankulor; Youngmi Kim; Sonali Arora; Julia Kargl; Frank Szulzewsky; Mark Hanke; Daciana H Margineantu; Aparna Rao; Hamid Bolouri; Jeff Delrow; David Hockenbery; A McGarry Houghton; Eric C Holland Journal: Genes Dev Date: 2017-05-02 Impact factor: 11.361